BCRX - BioCryst Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5373.96M
Enterprise Value 3350.46M
Trailing P/E N/A
Forward P/E 1-3.14
PEG Ratio (5 yr expected) 1-0.14
Price/Sales (ttm)16.57
Price/Book (mrq)16.62
Enterprise Value/Revenue 315.53
Enterprise Value/EBITDA 6-3.72

Trading Information

Stock Price History

Beta (3Y Monthly) 1.83
52-Week Change 3-41.02%
S&P500 52-Week Change 36.70%
52 Week High 39.9500
52 Week Low 32.8000
50-Day Moving Average 33.5669
200-Day Moving Average 36.8957

Share Statistics

Avg Vol (3 month) 32.33M
Avg Vol (10 day) 31.06M
Shares Outstanding 5110.31M
Float 60.15M
% Held by Insiders 11.04%
% Held by Institutions 193.64%
Shares Short (Jun 28, 2019) 412.58M
Short Ratio (Jun 28, 2019) 44.81
Short % of Float (Jun 28, 2019) 415.40%
Short % of Shares Outstanding (Jun 28, 2019) 411.40%
Shares Short (prior month May 31, 2019) 411.11M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019


Profit Margin 0.00%
Operating Margin (ttm)-421.18%

Management Effectiveness

Return on Assets (ttm)-39.90%
Return on Equity (ttm)-251.96%

Income Statement

Revenue (ttm)22.56M
Revenue Per Share (ttm)0.21
Quarterly Revenue Growth (yoy)48.10%
Gross Profit (ttm)-64.71M
EBITDA -94.28M
Net Income Avi to Common (ttm)-106.53M
Diluted EPS (ttm)-1.0040
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)107.56M
Total Cash Per Share (mrq)0.98
Total Debt (mrq)84.06M
Total Debt/Equity (mrq)373.47
Current Ratio (mrq)1.77
Book Value Per Share (mrq)0.20

Cash Flow Statement

Operating Cash Flow (ttm)-99.91M
Levered Free Cash Flow (ttm)-55.84M